Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Cash from Operations (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Cash from Operations for 13 consecutive years, with 133460000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations fell 27.73% to 133460000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 189553000.0, a 58.39% increase, with the full-year FY2025 number at 189553000.0, up 58.39% from a year prior.
  • Cash from Operations was 133460000.0 for Q4 2025 at Madrigal Pharmaceuticals, down from 79850000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 79850000.0 in Q3 2025 to a low of 149157000.0 in Q1 2024.
  • A 5-year average of 68906450.0 and a median of 63026500.0 in 2022 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: plummeted 93.26% in 2021, then skyrocketed 219.21% in 2025.
  • Madrigal Pharmaceuticals' Cash from Operations stood at 48051000.0 in 2021, then fell by 21.78% to 58515000.0 in 2022, then plummeted by 36.6% to 79933000.0 in 2023, then crashed by 30.72% to 104486000.0 in 2024, then decreased by 27.73% to 133460000.0 in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Cash from Operations are 133460000.0 (Q4 2025), 79850000.0 (Q3 2025), and 47052000.0 (Q2 2025).